June 20 - 21 2024



Equitable Access to Advanced Biomarker Testing for Canadian Metastatic Cancer Patients:
The Role of Patient Reported Outcomes, Real World Evidence, and Market Entry Schemes Across Multiple Tumour Types
A Warm Welcome from CCRAN’s President & CEO
Dear Friends:

On behalf of the Colorectal Cancer Resource & Action Network (CCRAN), welcome to the second annual, pan-tumour Biomarkers Conference focusing on timely and equitable access to biomarker testing results and comprehensive genomic profiling (CGP) for all metastatic cancer patients in Canada.

We are thrilled to once again be collaborating with multiple cancer patient advocacy groups, as we come together collectively to address the challenges and barriers in respect of biomarker testing and CGP to improve patient outcomes, challenge healthcare inequities, and drive value in the healthcare system in Canada.

This year’s Conference builds on the objectives and outcomes of the inaugural 2023 event. Working closely with other patient advocacy groups across Canada, our Conference will convene clinical, policy, research, and patient experts to examine:
  • Challenges, barriers and opportunities in biomarker testing and comprehensive genomic profiling
  • Implementation and policy considerations to move the needle forward for comprehensive genomic profiling as a future standard of cancer care in Canada
  • The business case for optimizing access to precision medicines and the role of real-world evidence in decision-making
  • The utility of ctDNA in clinical practice in the adjuvant and metastatic disease settings
  • Patients’ lived experience and reported outcomes regarding access to biomarker testing results and comprehensive genomic profiling across cancer types.

Precision medicine is transforming cancer care and providing significant benefits to people living with different types of cancer. But it can only achieve these benefits through wide and timely access to advanced biomarker testing or comprehensive genomic profiling. Join us for engaging and thought-provoking discussion with experts across Canada and internationally.

CCRAN will happily serve as a resource on each of these topics post Conference; hence, we welcome inquiries and outreach. We look forward to your online engagement on June 20th and 21st. Please do not hesitate to reach out to us with any questions or concerns regarding our Conference to Cassandra Macaulay at Cassandra.m@ccran.org.

Warmly,

Filomena Servidio-Italiano

President & CEO, CCRAN
Conference Agenda
CONFERENCE AGENDA
Target Audience: Clinicians, Patients and Caregivers, Researchers, Policy Makers, Industry
DAY 1: THURSDAY, JUNE 20, 2024
Time Session Title Speakers
9:30 a.m. –
9:35 a.m.
Conference Opening (Day 1)
Dr. Monika Slovinec D’Angelo, Ph.D.
VBHC Green Belt Expert, Chief Research Officer, CCRAN
CCRAN works for and with patients to support their cancer care journeys. Through its advocacy, education, and research initiatives CCRAN strives to address challenges that impede optimal delivery of cancer care and patient outcomes in Canada. Timely access to biomarker testing results is one of these important challenges. This year’s Biomarker Conference will build on the program of the 2023 inaugural Conference. Over the course of two days we will again convene clinical, research, policy and patient experts from across multiple cancer types to delve deeper into the access issues in Canada.
Dr. Monika Slovinec D’Angelo, Ph.D.
VBHC Green Belt Expert, Chief Research Officer, CCRAN
9:35 a.m. –
9:45 a.m.
Welcome from CCRAN’s President (Day 1)
Filomena Servidio-Italiano, Hon B.Sc., B.Ed., M.A.
President & CEO, CCRAN

Allen Chankowsky
Patient expert; Best-selling & multi-award-winning author, patient advocate, AllenChankowsky.com
Precision medicines are guided by a tumour’s biomarker status and represent a tremendous advancement in cancer treatment. They offer new hope, but systemic barriers to accessing biomarker testing and results need to be addressed. Care and treatment gaps identified by patients served as the impetus for this Conference series.

This year’s program will cover multiple cancer types: Experts from within and outside of Canada will contribute knowledge and perspectives on opportunities for ameliorating access to biomarker testing and precision medicines in service of improving cancer patient care trajectories and outcomes.
Filomena Servidio-Italiano, Hon B.Sc., B.Ed., M.A.
President & CEO, CCRAN

Allen Chankowsky
Patient expert; Best-selling & multi-award-winning author, patient advocate, AllenChankowsky.com
9:45 a.m. –
10:15 a.m.
Barriers and Unequal Access to Timely Molecular Testing Results: Addressing the Inequities in Cancer Care Delays Across Canada
Dr. Stephanie Snow, MD, FRCPC
Medical Oncologist, QEII Health Sciences Centre; Professor, Faculty of Medicine, Dalhousie University; President, Lung Cancer Canada
In 2023, CCRAN hosted their first pan-tumour Biomarkers Conference which highlighted the importance of timely biomarker testing across cancer types and addressed the barriers that patients and clinicians experience in accessing results in a timely manner to inform treatment decision-making. The objectives, outcomes of expert discussions, and calls to action from this inaugural event are summarized in a published paper (Current Oncology). They highlight the pertinence of broader application of biomarker testing and genomic profiling in optimizing cancer care. This year’s Conference builds on the objectives and outcomes of the inaugural event. Dr. Stephanie Snow, co-author, will speak to the objectives and key themes that arose from the 2023 Conference sessions.
Dr. Stephanie Snow, MD, FRCPC
Medical Oncologist, QEII Health Sciences Centre; Professor, Faculty of Medicine, Dalhousie University; President, Lung Cancer Canada
10:15 a.m. –
11:15 a.m.
Results of a National Pan-Tumour Survey Regarding Access to Biomarker Testing Results: What are Canadian Advanced Cancer Patients Saying?
Dr. Monika Slovinec D’Angelo, Ph.D.
VBHC Green Belt Expert, Chief Research Officer, CCRAN

Cassandra Macaulay, BSc, MHS, RTNM
Senior Manager of Programs & Education, CCRAN

Filomena Servidio-Italiano, Hon B.Sc., B.Ed., M.A.
President & CEO, CCRAN
CCRAN is leading a collaborative research project on the patients’ lived experience and outcomes related to accessing biomarker testing and results as well as comprehensive genomic profiling to better understand the benefits of facilitating access in Canada from the patient perspective across cancer types.

Working with multiple advocacy groups representing a number of cancer types, CCRAN is promoting cross-learning and building capacity for system-level and policy changes required to optimize access to genomic profiling throughout the care trajectory and thereby patient outcomes.

This research will also identify patient and healthcare provider knowledge gaps and education needs to help inform knowledge translation efforts, support patient engagement and advocacy efforts, and for developing evidence-based clinical practice guidelines for biomarker testing across cancer types. The patient information will be related to healthcare system elements, infrastructures and initiatives at the province-level to help identify policies and best practices for building capacity for optimizing access to genomic testing.
Dr. Monika Slovinec D’Angelo, Ph.D.
VBHC Green Belt Expert, Chief Research Officer, CCRAN

Cassandra Macaulay, BSc, MHS, RTNM
Senior Manager of Programs & Education, CCRAN

Filomena Servidio-Italiano, Hon B.Sc., B.Ed., M.A.
President & CEO, CCRAN
11:15 a.m. –
12:15 p.m.
Collaborative Advocacy Strategies for Addressing Biomarker Testing Access Issues Across Tumour Types
Patient Group Roundtable:

Martha Raymond, MA, CPN (Moderator)
Founder/CEO, The Raymond Foundation; Founding Executive Director, GI Cancers Alliance Inc. (US)

Patient Organizations:

Teresa Norris
Cervical Cancer. Founder and President, HPV Global Action

Richelle Laturnus, BSc
Prostate Cancer. Support Services Manager, Prostate Cancer Foundation Canada

Ken Noel
Executive Director, The Walnut Foundation

Allen Chankowsky
Salivary Gland Cancer. Best-selling & multi-award-winning author, Patient Advocate, AllenChankowsky.com

Martine Elias
Myeloma/Blood Cancers. Executive Director, Myeloma Canada

Brenda Clayton, MN
Liver Cancer (hepatocellular carcinoma and cholangiocarcinoma). Founder, Cholangio-Hepatocellular Carcinoma Canada

Maura Cosgrave
Childhood Cancers. ACCESS/PROFYLE and Childhood Cancer Canada
This roundtable will engage leads from patient groups representing different cancer types in a dialogue on strategic opportunities for addressing some of the issues highlighted by the results of the National pan-tumour survey on access to biomarker testing. The cancer group leads will elaborate on the survey findings from the perspective of their respective patient population.

The dialogue will serve to emphasize priorities for advocacy efforts and identify opportunities for strategic collaborations aimed at promoting timely access to biomarker testing and precision therapies. The discussion will also hone in on the value, collection, and utility of patient reported data for generating real world evidence and informing research and advocacy efforts. Patient group perspectives on questions related to data registries, including those related to governance, funding, and data sharing concerns (privacy and ethics), will be addressed.
Patient Group Roundtable:

Martha Raymond, MA, CPN (Moderator)
Founder/CEO, The Raymond Foundation; Founding Executive Director, GI Cancers Alliance Inc. (US)

Patient Organizations:

Teresa Norris
Cervical Cancer. Founder and President, HPV Global Action

Richelle Laturnus, BSc
Prostate Cancer. Support Services Manager, Prostate Cancer Foundation Canada

Ken Noel
Executive Director, The Walnut Foundation

Allen Chankowsky
Salivary Gland Cancer. Best-selling & multi-award-winning author, Patient Advocate, AllenChankowsky.com

Martine Elias
Myeloma/Blood Cancers. Executive Director, Myeloma Canada

Brenda Clayton, MN
Liver Cancer (hepatocellular carcinoma and cholangiocarcinoma). Founder, Cholangio-Hepatocellular Carcinoma Canada

Maura Cosgrave
Childhood Cancers. ACCESS/PROFYLE and Childhood Cancer Canada
12:15 p.m. –
1:00 p.m.
Health Break – Educational Videos
1:00 p.m. –
2:15 p.m.
Tackling the Implementation Gap for the Uptake of Advanced Molecular Testing into Healthcare Systems: What are the Priorities?
Panel Session

Dr. Yvonne Bombard, PhD (Moderator)
Canada Research Chair in Genomics Health Services and Policy; Associate Professor, IHPME, UofT; Director, Genomics Health Services Research Program & Scientist, LKSKI, St. Michael's Hospital, UHN; Co-Founder & CEO, Genetics Adviser

Dr. Denis Horgan, PhD, LLM, MSc, BCL
Executive Director, European Alliance of Personalised Medicine (EAPM); Editor in Chief, Public Health Genomics Journal; Stakeholder Advisory Group Chair, International Cancer Genome Consortium

Dr. Laura Weeks, PhD
Director, Health Technology Assessment Canadian Agency for Drugs and Technologies in Health

Dr. Alan Spatz, MD, MSc
Professor, Departments of Pathology and Oncology, McGill University; Chief, Department of Clinical laboratory medicine, McGill University Health Center (MUHC); Medical director, Optilab Montreal-MUHC network

Dr. Michael Mengel, MD
Chair & Medical Director, Laboratory Medicine & Pathology, University of Alberta; Medical Director, Alberta Precision Laboratories Ltd.

Craig Ivany, MBA
Chief Provincial Diagnostic Officer, Provincial Health Services Authority (PHSA), British Columbia

Dr. Harriet Feilotter, PhD, FCCMG
Division Head, Genome Diagnostics, Laboratory Medicine Program, University Health Network; Service Chief, Laboratory Genetics, Kingston Health Sciences Centre; Professor (Adjunct), Department of Pathology and Molecular Medicine, Queen’s University
Advanced molecular testing, specifically comprehensive genomic profiling (CGP), enables timely and accurate cancer diagnosis and enables the selection of the most appropriate treatment options for patients. Access to next generation sequencing (NGS) technologies, however, is currently very limited in Canadian jurisdictions, depriving patients of the benefits afforded by innovations in precision medicine.

This session brings together the perspectives of Canadian and international experts in genomics, health technology assessment, laboratory medicine, and health policy in a discussion on key priorities for promoting the implementation of NGS in clinical practice in service of optimizing patient care and treatment outcomes.

Canadian experts will speak to the current state of readiness for advanced molecular testing across provinces; structural, operational and regulatory challenges with respect to implementation and equitable access; and practical opportunities for narrowing the implementation and access gap. A genomics expert from Europe will elaborate on current utilization of NGS and CGP in oncology, access challenges, as well as strategies being used to accelerate and expand the delivery and uptake of personalized medicine and diagnostics in EU member states.

Promising models and funding approaches for more collaborative and rapid implementation of CGP in healthcare systems to optimize patient access to precision medicine will be considered.
Panel Session

Dr. Yvonne Bombard, PhD (Moderator)
Canada Research Chair in Genomics Health Services and Policy; Associate Professor, IHPME, UofT; Director, Genomics Health Services Research Program & Scientist, LKSKI, St. Michael's Hospital, UHN; Co-Founder & CEO, Genetics Adviser

Dr. Denis Horgan, PhD, LLM, MSc, BCL
Executive Director, European Alliance of Personalised Medicine (EAPM); Editor in Chief, Public Health Genomics Journal; Stakeholder Advisory Group Chair, International Cancer Genome Consortium

Dr. Laura Weeks, PhD
Director, Health Technology Assessment Canadian Agency for Drugs and Technologies in Health

Dr. Alan Spatz, MD, MSc
Professor, Departments of Pathology and Oncology, McGill University; Chief, Department of Clinical laboratory medicine, McGill University Health Center (MUHC); Medical director, Optilab Montreal-MUHC network

Dr. Michael Mengel, MD
Chair & Medical Director, Laboratory Medicine & Pathology, University of Alberta; Medical Director, Alberta Precision Laboratories Ltd.

Craig Ivany, MBA
Chief Provincial Diagnostic Officer, Provincial Health Services Authority (PHSA), British Columbia

Dr. Harriet Feilotter, PhD, FCCMG
Division Head, Genome Diagnostics, Laboratory Medicine Program, University Health Network; Service Chief, Laboratory Genetics, Kingston Health Sciences Centre; Professor (Adjunct), Department of Pathology and Molecular Medicine, Queen’s University
2:15 p.m. –
2:30 p.m.
Health Break – Educational Videos
2:30 p.m. –
3:30 p.m.
Delivering on the Promise of Precision Oncology: Efficacy and Turn-Around Time for Biomarker Testing
Presentations & Panel Session
Dr. Shaan Dudani, MD, MBChB, MPH, FRCPC (Moderator)
Medical Oncologist, William Osler Health System; Assistant Professor, University of Toronto

Experts

Emmanuelle Langelier
Caregiver to her husband, stage 4 rectal cancer patient

Dr. Brandon Sheffield, MD, FRCPC
Medical Director of Advanced Diagnostics, William Osler Health System; Mississauga Halton Central West Regional Pathology Lead

Dr. Harriet Feilotter, PhD, FCCMG
Division Head, Genome Diagnostics, Laboratory Medicine Program, University Health Network; Service Chief, Laboratory Genetics, Kingston Health Sciences Centre; Professor (Adjunct), Department of Pathology and Molecular Medicine, Queen’s University

Dr. Stephen Yip
Associate Professor, UBC; Clinician-Scientist, Neuropathologist, BCCA; Associate Member at Canada’s Michael Smith Genome Sciences Centre

Dr. Michael Carter, MD, PhD, FRCPC
Medical Director, Molecular Diagnostics, Nova Scotia Health; Medical Director of Research, Division of Anatomical Pathology; Co-Chair, Molecular Oncology Diagnostic Testing Provincial Stewardship Committee for Nova Scotia Health

Dr. Nicola Normanno, MD
Scientific Director, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
Precision cancer care is contingent on laboratory-based biomarker testing, with optimal treatment decisions being predicated on biomarker data. However, significant gaps in biomarker delivery exist in Canada’s publicly funded healthcare system, with patients and clinicians waiting too long to receive biomarker test results, often rendering them meaningless to guide precision medicine.

Implementation of “better practices” for biomarker testing and reporting opens the door for equitable access to precision medicine, facilitating access to optimal treatment options that ameliorate patient care trajectories.

In this session, Canadian medical and laboratory experts will describe evidence-based practices for improving the timely delivery, and thereby utility, of accurate and reliable cancer biomarker results. While acknowledging the complexities of next-generation sequencing (NGS) methodologies, funding constraints, and infrastructural obstacles, experts will address challenges within the molecular diagnostic pathway, from sample collection to reporting of results, with a focus on optimizing the efficiency and quality of pathological laboratory processes and procedures. The critical role of systematic quality assurance in molecular diagnostics will be explained, and a novel end-to-end proficiency testing approach showcased. Advantages of standardizing laboratory processes within and across provinces in Canada in improving timely and equitable access to quality diagnostics and optimal treatment options will be considered.
Presentations & Panel Session
Dr. Shaan Dudani, MD, MBChB, MPH, FRCPC (Moderator)
Medical Oncologist, William Osler Health System; Assistant Professor, University of Toronto

Experts

Emmanuelle Langelier
Caregiver to her husband, stage 4 rectal cancer patient

Dr. Brandon Sheffield, MD, FRCPC
Medical Director of Advanced Diagnostics, William Osler Health System; Mississauga Halton Central West Regional Pathology Lead

Dr. Harriet Feilotter, PhD, FCCMG
Division Head, Genome Diagnostics, Laboratory Medicine Program, University Health Network; Service Chief, Laboratory Genetics, Kingston Health Sciences Centre; Professor (Adjunct), Department of Pathology and Molecular Medicine, Queen’s University

Dr. Stephen Yip
Associate Professor, UBC; Clinician-Scientist, Neuropathologist, BCCA; Associate Member at Canada’s Michael Smith Genome Sciences Centre

Dr. Michael Carter, MD, PhD, FRCPC
Medical Director, Molecular Diagnostics, Nova Scotia Health; Medical Director of Research, Division of Anatomical Pathology; Co-Chair, Molecular Oncology Diagnostic Testing Provincial Stewardship Committee for Nova Scotia Health

Dr. Nicola Normanno, MD
Scientific Director, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
3:30 p.m. –
4:45 p.m.
The Utility and Feasibility of Comprehensive Genomic Profiling (CGP) in Clinical Practice
Clinician Roundtable:

Dr. Christopher Lieu, MD (Moderator)
Associate Professor, Director, GI Oncology, University of Colorado

Experts:

Dr. Michael Raphael, MD, FRCPC
Medical Oncologist, Odette Cancer Center at Sunnybrook Health Sciences Centre

Dr. Mita Manna, MD, FRCPC
Medical Oncologist, Provincial Disease Site Lead for Breast Malignancies, Saskatoon Cancer Centre

Dr. Shaqil Kassam, MD, MSc, FRCPC
Medical Oncologist, Southlake Stronach Regional Cancer Centre

Dr. Neesha Dhani, MD, PhD, FRCPC
Staff Medical Oncologist, Clinician-Investigator, Gynecologic Cancers Disease Site Group, Medical Director, Inpatient Services, UHN - Princess Margaret Cancer Centre, Division of Medical Oncology & Hematology

Dr. Ravi Ramjeesingh, MD, Ph.D, FRCPC
Medical Oncologist & Assistant Professor; Chair of the HPB Cancer Disease Site Group Halifax, Division of Medical Oncology and Department of Community Health and Epidemiology, Nova Scotia Cancer Centre & Dalhousie University
Medical experts, specializing in colorectal, breast, lung, gynecologic, and pancreatic, cholangiocarcinoma and liver cancers, will engage in a dialogue on the value of comprehensive genomic profiling (CGP) in clinical practice, in terms of current benefits and untapped opportunities.

This session will highlight differences in how CGP is being accessed and used in diagnostic and treatment care pathways across cancers and Canadian jurisdictions. Educational needs and strategies for expanding clinician utilization of CGP will be addressed, with a focus on what it will take to implement CGP as a standard of care for advanced cancer patients in Canada. Benefits of CGP and management of patient expections with respect to treatment results and health outcomes will be considered.
Clinician Roundtable:

Dr. Christopher Lieu, MD (Moderator)
Associate Professor, Director, GI Oncology, University of Colorado

Experts:

Dr. Michael Raphael, MD, FRCPC
Medical Oncologist, Odette Cancer Center at Sunnybrook Health Sciences Centre

Dr. Mita Manna, MD, FRCPC
Medical Oncologist, Provincial Disease Site Lead for Breast Malignancies, Saskatoon Cancer Centre

Dr. Shaqil Kassam, MD, MSc, FRCPC
Medical Oncologist, Southlake Stronach Regional Cancer Centre

Dr. Neesha Dhani, MD, PhD, FRCPC
Staff Medical Oncologist, Clinician-Investigator, Gynecologic Cancers Disease Site Group, Medical Director, Inpatient Services, UHN - Princess Margaret Cancer Centre, Division of Medical Oncology & Hematology

Dr. Ravi Ramjeesingh, MD, Ph.D, FRCPC
Medical Oncologist & Assistant Professor; Chair of the HPB Cancer Disease Site Group Halifax, Division of Medical Oncology and Department of Community Health and Epidemiology, Nova Scotia Cancer Centre & Dalhousie University
4:45 p.m. –
5:00 p.m.
Closing Remarks
Filomena Servidio-Italiano, Hon B.Sc., B.Ed., M.A.
President & CEO, CCRAN
Call to action on policy priorities for biomarker testing and reporting in oncology.
Filomena Servidio-Italiano, Hon B.Sc., B.Ed., M.A.
President & CEO, CCRAN
CONFERENCE AGENDA
Target Audience: Clinicians, Patients and Caregivers, Researchers, Policy Makers, Industry
DAY 2: FRIDAY, JUNE 21, 2024
Time Session Title Presenters/Speakers
9:30 a.m. –
9:35 a.m.
Conference Opening (Day 2)
Dr. Monika Slovinec D’Angelo, Ph.D.
VBHC Expert, Chief Research Officer, CCRAN
9:35 a.m. –
9:45 a.m.
Welcome from CCRAN’s President (Day 2)
Filomena Servidio-Italiano, Hon B.Sc., B.Ed., M.A.
President & CEO, CCRAN

Laura Greer
Patient Expert; Senior Vice President and National Health Sector Lead, Health and Wellness, Hill & Knowlton; Breast cancer advocate
Recap of Conference Day 1.
Filomena Servidio-Italiano, Hon B.Sc., B.Ed., M.A.
President & CEO, CCRAN

Laura Greer
Patient Expert; Senior Vice President and National Health Sector Lead, Health and Wellness, Hill & Knowlton; Breast cancer advocate
9:45 a.m. –
10:15 a.m.
Equitable Access to Genomic Medicine in Canada: Bridging the Divide Between What Could be and What is through Investment and Communication Strategies
Presentations:
Laura Greer
Senior Vice President and National Health Sector Lead, Health and Wellness, Hill & Knowlton; Breast cancer advocate

Dr. Catalina Lopez-Correa, MD, PhD
Chief Scientific Officer, Genome Canada
Genomic biomarkers are a cornerstone of progress in cancer treatment. Canada’s healthcare system, however, is not ready for where science is taking us and lags in enabling patient access to advancements in genomic medicine. This session highlights two calls to action to bridge the gap between scientific progress and patient access to its clinical application. Namely, strategic investment in genomic testing infrastructure and rollout of targeted communication strategies.

A genomic scientist will discuss biomarker testing's transformative potential in oncology, current gaps in patient access to scientific discoveries, and opportunities for enhancing equitable access. A communications professional will speak to the role of advocacy in improving access to optimal care, and elaborate on strategies for bolstering individual and system-level advocacy efforts through education and evidence-based information sharing. Both experts bring personal experiences as cancer patients navigating cancer testing and treatment.
Presentations:
Laura Greer
Senior Vice President and National Health Sector Lead, Health and Wellness, Hill & Knowlton; Breast cancer advocate

Dr. Catalina Lopez-Correa, MD, PhD
Chief Scientific Officer, Genome Canada
10:15 a.m. –
11:15 a.m.
The Utility and Feasibility of ctDNA Testing for Minimal Residual Disease (MRD) in Optimizing Cancer Care in Adjuvant & Metastatic Disease Settings
Clinician Roundtable:

Dr. Sharlene Gill, MD, MPH, MBA (Moderator)
Professor of Medicine, UBC; Medical Oncologist, BC Cancer, Vancouver; President, Canadian Association of Medical Oncologists

Experts:

Dr. Pashtoon M. Kasi, MD, MS
Oncologist and Researcher, Weill Cornell Medicine and New York-Presbyterian Hospital; Director for Colorectal Cancer Research, Weill Cornell Medicine; Precision Medicine Director for Liquid Biopsy Research, Englander Institute of Precision Medicine

Prof. Klaus Pantel
Chairman, Institute of Tumor Biology, University Medical Center Hamburg-Eppendorf (UKE)

Dr. Christine Brezden-Masley, MD, PhD, FRCPC
Senior Practicing Medical Oncologist and Medical Director, Cancer Program, Sinai Health System; Director, Marvelle Koffler Breast Centre, Sinai Health System; Associate Professor, Temerty Faculty of Medicine, University of Toronto; Associate Scientist, Lunenfeld-Tanenbaum Research Institute

Dr. Michael Raphael, MD, FRCPC
Medical Oncologist, Odette Cancer Center at Sunnybrook Health Sciences Centre

Dr. Joao Paulo Solar Vasconcelos, MD
Gastrointestinal Medical Oncology Fellow, BC Cancer, Vancouver

Dr. Ceilidh MacPhail, MSc, MD
Medical Oncologist, Nova Scotia Cancer Center
This session will engage medical experts, specializing in lung, breast, and colorectal cancers, and MSI high disease, in a discourse on the value and practical utility of ctDNA in adjuvant and metastatic disease settings. Focus will be on detection of minimal residual disease (MRD) for cancer types where treatment decisions and the patient care trajectory may benefit from ctDNA testing.

Medical experts practicing in Canada, Europe and the US will speak to current guidelines and application of ctDNA testing in clinical care. The use of ctDNA testing for MRD will be compared between jurisdictions, and its value in optimizing treatment pathways and patient outcomes elaborated on.
Clinician Roundtable:

Dr. Sharlene Gill, MD, MPH, MBA (Moderator)
Professor of Medicine, UBC; Medical Oncologist, BC Cancer, Vancouver; President, Canadian Association of Medical Oncologists

Experts:

Dr. Pashtoon M. Kasi, MD, MS
Oncologist and Researcher, Weill Cornell Medicine and New York-Presbyterian Hospital; Director for Colorectal Cancer Research, Weill Cornell Medicine; Precision Medicine Director for Liquid Biopsy Research, Englander Institute of Precision Medicine

Prof. Klaus Pantel
Chairman, Institute of Tumor Biology, University Medical Center Hamburg-Eppendorf (UKE)

Dr. Christine Brezden-Masley, MD, PhD, FRCPC
Senior Practicing Medical Oncologist and Medical Director, Cancer Program, Sinai Health System; Director, Marvelle Koffler Breast Centre, Sinai Health System; Associate Professor, Temerty Faculty of Medicine, University of Toronto; Associate Scientist, Lunenfeld-Tanenbaum Research Institute

Dr. Michael Raphael, MD, FRCPC
Medical Oncologist, Odette Cancer Center at Sunnybrook Health Sciences Centre

Dr. Joao Paulo Solar Vasconcelos, MD
Gastrointestinal Medical Oncology Fellow, BC Cancer, Vancouver

Dr. Ceilidh MacPhail, MSc, MD
Medical Oncologist, Nova Scotia Cancer Center
11:15 a.m. –
12:00 p.m.
Research into Practice: Biomarker Driven Patient Education Tools
Presentations:
Dr. Yvonne Bombard, PhD
Canada Research Chair in Genomics Health Services and Policy; Associate Professor, Institute of Health Policy, Management and Evaluation, University of Toronto; Director, Genomics Health Services Research Program & Scientist, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Unity Health Toronto; Co-Founder & CEO, Genetics Adviser

Filomena Servidio-Italiano, Hon B.Sc., B.Ed., M.A.
President & CEO, CCRAN

Dr. Mary De Vera, B.Sc., M.Sc., Ph.D.
Epidemiologist; Associate Professor, UBC; Tier 2 Canada Research Chair in Health Outcomes and Treatment Adherence
Patient education and understanding of the implications of biomarker testing will be discussed in this session. Patient education experts will present on biomarker-driven online tools presently available for patients. An epidemiologist will speak to the findings from a research study evaluating colorectal cancer patients’ perspectives and attitudes towards biomarker testing.
Presentations:
Dr. Yvonne Bombard, PhD
Canada Research Chair in Genomics Health Services and Policy; Associate Professor, Institute of Health Policy, Management and Evaluation, University of Toronto; Director, Genomics Health Services Research Program & Scientist, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Unity Health Toronto; Co-Founder & CEO, Genetics Adviser

Filomena Servidio-Italiano, Hon B.Sc., B.Ed., M.A.
President & CEO, CCRAN

Dr. Mary De Vera, B.Sc., M.Sc., Ph.D.
Epidemiologist; Associate Professor, UBC; Tier 2 Canada Research Chair in Health Outcomes and Treatment Adherence
12:00 p.m. –
1:00 p.m.
Health Break – Educational Videos
1:00 p.m. –
2:00 p.m.
Examining Policy Recommendations for Accelerating Access to Precision Medicine through a Value-Based Healthcare Lens
Panel Session:
Dr. Monika Slovinec D’Angelo, Ph.D. (Moderator)
VBHC Green Belt Expert, Chief Research Officer, CCRAN

Experts:

Fred Horne, ECA, MBA
Principal, Horne and Associates, Health Policy Consultants; Canadian Health Policy Consultant; Former Alberta Minister of Health

Dr. Darren Larsen, MD, CCFP, MPL
Chair, Cancer Quality Council of Ontario; Board Director, Canadian Partnership Against Cancer; Senior fellow, Women’s College Hospital Institute for Health System Solutions and Virtual Care; Lecturer, Department of Family and Community Medicine and Institute for Health Policy Management and Evaluation, University of Toronto

Dr. David J. Stewart, MD
Professor of Medicine, Division of Medical Oncology, University of Ottawa and The Ottawa Hospital

Dr. Christopher Booth, MD, FRCPC
Professor and Medical Oncologist, Queen's University and Kingston Health Sciences Centre
Health system transformation experts will elaborate on the issue of equitable access to advanced molecular diagnostics and precision therapies, and the meaning of value from a healthcare expenditure and population health perspective. The value and cost of improving equitable access to precision medicine will be examined through the lens of patients, healthcare providers, population health, and health systems. The role of private industry, health technology assessment bodies, and payers in delivering on the promise of precision medicine will be considered.
Panel Session:
Dr. Monika Slovinec D’Angelo, Ph.D. (Moderator)
VBHC Green Belt Expert, Chief Research Officer, CCRAN

Experts:

Fred Horne, ECA, MBA
Principal, Horne and Associates, Health Policy Consultants; Canadian Health Policy Consultant; Former Alberta Minister of Health

Dr. Darren Larsen, MD, CCFP, MPL
Chair, Cancer Quality Council of Ontario; Board Director, Canadian Partnership Against Cancer; Senior fellow, Women’s College Hospital Institute for Health System Solutions and Virtual Care; Lecturer, Department of Family and Community Medicine and Institute for Health Policy Management and Evaluation, University of Toronto

Dr. David J. Stewart, MD
Professor of Medicine, Division of Medical Oncology, University of Ottawa and The Ottawa Hospital

Dr. Christopher Booth, MD, FRCPC
Professor and Medical Oncologist, Queen's University and Kingston Health Sciences Centre
2:00 p.m. –
3:00 p.m.
The Interplay Between Genomic Profiling and Real-World Evidence in Precision Medicine: Optimizing Cancer Care and Facilitating Payer Decisions
Panel Session:

Dr. Monika Slovinec D’Angelo, Ph.D., VBHC (Moderator)
VBHC Green Belt, Expert, Chief Research Officer, CCRAN

Experts:

Louise Binder, B.A., LL.B, LL.D (hon ), O.Ont.
Health Advocate and Health Policy Consultant, CONECTed - Save Your Skin Foundation

Filomena Servidio-Italiano, Hon B.Sc., B.Ed., M.A.
President & CEO, CCRAN
To speak to the importance of genomic profiling in improving patient outcomes

Dr. Shaqil Kassam, MD, MSc, FRCPC
Medical Oncologist, Southlake Stronach Regional Cancer Centre

Dr. Jason Karamchandani, MD
Associate Professor, Departments of Pathology, Neurology and Neurosurgery, McGill University; President, Canadian Association of Pathologists

Sang Mi Lee, MBA, BSc Phm, RPh
Executive Director, MORSE Consulting Inc.
This discussion will elaborate on the business case for optimizing access to precision medicine that Canadian Health Advocate, Louise Binder, co-authored, with a deep dive into how real-world evidence is generated and used to accelerate access to precision therapies in service of improving clinical care and patient-reported outcomes.

Panelists will speak to how real-world evidence (RWE) can be collected and leveraged to guide clinical and payer decision-making, and conversely how providing earlier access to genomic profiling and precision therapies is required to generate reliable RWE. Within this context, the role and practical implementation of managed entry agreements will also be elaborated on, with reference to some successful examples from Canada and international jurisdictions.
Panel Session:

Dr. Monika Slovinec D’Angelo, Ph.D., VBHC (Moderator)
VBHC Green Belt, Expert, Chief Research Officer, CCRAN

Experts:

Louise Binder, B.A., LL.B, LL.D (hon ), O.Ont.
Health Advocate and Health Policy Consultant, CONECTed - Save Your Skin Foundation

Filomena Servidio-Italiano, Hon B.Sc., B.Ed., M.A.
President & CEO, CCRAN
To speak to the importance of genomic profiling in improving patient outcomes

Dr. Shaqil Kassam, MD, MSc, FRCPC
Medical Oncologist, Southlake Stronach Regional Cancer Centre

Dr. Jason Karamchandani, MD
Associate Professor, Departments of Pathology, Neurology and Neurosurgery, McGill University; President, Canadian Association of Pathologists

Sang Mi Lee, MBA, BSc Phm, RPh
Executive Director, MORSE Consulting Inc.
3:00 p.m. –
4:00 p.m.
Feasible Opportunities to Adopt Comprehensive Genomic Profiling in Canada: An International Perspective
Panel Session:

Don Husereau, BSc Pharm, MSc (Moderator)
Adjunct Professor of Medicine, University of Ottawa

Experts:
Prof. David M. Thomas
Director, Centre for Molecular Oncology, University of New South Wales; Head of the Genomic Cancer Medicine Laboratory, Garvan Institute of Medical Research; CEO of Omico

Dr. Shantanu Banerji, BSc(Med), MD, FRCPC
Medical Oncologist, CancerCare Manitoba, MacCharles Site; Senior Scientist, Research Institute in Haematology and Oncology, CancerCare Manitoba; Director, Precision Oncology and Advanced Therapeutics, CancerCare Manitoba; Assistant Professor, Department of Internal Medicine, Section of Haematology/ Oncology, University of Manitoba

Dr. Cathy Eng, MD, FACP, FASCO
Vanderbilt-Ingram Cancer Center, Nashville, TN; David H. Johnson Chair in Surgical and Medical Oncology; Professor of Medicine, Hematology and Oncology; Director for Strategic Relations; Co-Director, GI Oncology; Co-Leader, Gastrointestinal Cancer Research Program; Director, Young Adult Cancers Program; Co-Chair, NCI Gastrointestinal Steering Committee

Prof. Dr. Patrick Pauwels, MD, PhD
Head of the Laboratory of Molecular Pathology & Co-Director of the Center of Oncology Research (CORE), Antwerp University; Professor in Molecular Oncopathology, Antwerp University; Scientific Advisor, Luxemburg National Health Service
Experts in the field of genomic medicine will engage in a dialogue on how the use of genomic profiling in clinical practice has evolved, and the opportunities for broader application of comprehensive genomic profiling (CGP) given advancements in technology and precision medicine. The tension between system-level capacity issues (e.g., costs, training, guideline development and translation into practice, infrastructure and standardizing processes) and the inherent value to patient care and outcomes will be elaborated on to identify priorities for practical solutions. Perspectives and insights from experts in Canada, Europe, Australia, the UK and the US will be represented.
Panel Session:

Don Husereau, BSc Pharm, MSc (Moderator)
Adjunct Professor of Medicine, University of Ottawa

Experts:
Prof. David M. Thomas
Director, Centre for Molecular Oncology, University of New South Wales; Head of the Genomic Cancer Medicine Laboratory, Garvan Institute of Medical Research; CEO of Omico

Dr. Shantanu Banerji, BSc(Med), MD, FRCPC
Medical Oncologist, CancerCare Manitoba, MacCharles Site; Senior Scientist, Research Institute in Haematology and Oncology, CancerCare Manitoba; Director, Precision Oncology and Advanced Therapeutics, CancerCare Manitoba; Assistant Professor, Department of Internal Medicine, Section of Haematology/ Oncology, University of Manitoba

Dr. Cathy Eng, MD, FACP, FASCO
Vanderbilt-Ingram Cancer Center, Nashville, TN; David H. Johnson Chair in Surgical and Medical Oncology; Professor of Medicine, Hematology and Oncology; Director for Strategic Relations; Co-Director, GI Oncology; Co-Leader, Gastrointestinal Cancer Research Program; Director, Young Adult Cancers Program; Co-Chair, NCI Gastrointestinal Steering Committee

Prof. Dr. Patrick Pauwels, MD, PhD
Head of the Laboratory of Molecular Pathology & Co-Director of the Center of Oncology Research (CORE), Antwerp University; Professor in Molecular Oncopathology, Antwerp University; Scientific Advisor, Luxemburg National Health Service
4:00 p.m. –
4:15 p.m.
Closing Remarks
Filomena Servidio-Italiano, Hon B.Sc., B.Ed., M.A.
President & CEO, CCRAN


With immense gratitude, we extend our thanks to the following patient advocacy groups for their collaboration on CCRAN’s 2024 Pan-Tumour Patient Survey, and for their participation in the Biomarkers Conference:


Picture of the Sponsor Logos.

CCRAN Gratefully Acknowledges the Conference's Supporting Sponsors

Platinum Level
Gold Level
Silver Level
Bronze Level
Click here to Register / View the Webcast




Webcast will open on Thursday June 20 at 9:00 AM EDT and will begin at 9:30 AM EDT. Add to calendar:  

Jun


20
This webcast requires pre-registration.

Steering Committee

photo

Dr. Sharlene Gill, Steering Committee Chair; MD, MPH, MBA; Professor of Medicine, UBC; Medical Oncologist, BC Cancer - Vancouver; President, Canadian Association of Medical Oncologists

Dr. Sharlene Gill is a Professor of Medicine at the University of British Columbia and a medical oncologist specializing in gastrointestinal (GI) malignancies at BC Cancer, Vancouver. She received a Bachelor of Science in Pharmacy and an MD from the University of British Columbia in 1996 followed by residencies in Internal Medicine and Medical Oncology. Dr. Gill subsequently completed a fellowship in Gl Oncology at the Mayo Clinic (Rochester, MN) and a Master of Public Health from the Harvard School of Public Health. In 2017, she completed an MBA from the Kenan-Flagler School of Business at the University of North Carolina. She is actively engaged in education and research, with over 120 peer-reviewed publications and book chapters to her credit. Dr. Gill serves as the Chair of the Canadian Clinical Trials Group (CCTG) GI Disease Site Committee and Chair of the UBC Department of Medicine Mentoring Committee. She is the Editor-in-Chief for Current Oncology and is the President of the Canadian Association of Medical Oncologists. Her TEDx talk in 2022 on ‘How to Flip the Script on Cancer’ delivered her passion for patient advocacy and empowerment.

photo

Dr. Christine Brezden-Masley, MD, PhD, FRCPC; Senior Practicing Medical Oncologist and Medical Director, Cancer Program, Sinai Health System; Director, Marvelle Koffler Breast Centre, Sinai Health System

Christine Brezden-Masley, MD, PhD, FRCPC is a senior practicing Medical Oncologist and the Medical Director of the Cancer Program at Sinai Health System in Toronto, Canada. She is also the Director of the Marvelle Koffler Breast Centre at Sinai Health and holds the Marvelle Koffler Chair in Breast Research. She obtained her PhD in Medical Biophysics at the Princess Margaret Hospital in Toronto and her Medical Degree from the University of Toronto. She is currently an Associate Professor at the Temerty Faculty of Medicine, University of Toronto and an Associate Scientist at the Lunenfeld-Tanenbaum Research Institute, Toronto, Canada.

She treats both breast and gastrointestinal (colorectal and gastric cancers) malignancies, which are her major areas of research interest. Her main area of clinical research is cardiotoxicity from cancer therapy and is the Past-President of the Canadian Cardio-Oncology Network (2017-2022). She also serves on the International Cardio-Oncology Society (ICOS) annual summit steering committees and co-chaired the 2022 Global Cardio-Oncology Summit in Toronto. She co-chairs the Junior Mentoring Program (JuMP) that fosters mentorship/sponsorship of junior medical oncology faculty across Canada and serves on the executive of WinC (Women in Cancer/All in Cancer). She is an advocate for patients and serves on CCRAN’s Medical & Scientific Advisory Board, and as a board member of ReThink Breast Cancer and MyGutFeeling.

photo

Mr. Allen Chankowsky, Patient expert; Best-selling & multi-award-winning author, patient advocate, AllenChankowsky.com

Allen Chankowsky is an acclaimed author, sought-after international speaker, and a resilient 33-year survivor of a rare form of stage-4 Androgen Receptor positive cancer. Best known for his multi-award-winning & best-selling book, "On the Other Side of TERMINAL", Allen inspires his audience with a powerful narrative of hope and resilience against one of life's gravest challenges.

Allen's contributions to the field extend far beyond his personal journey. An expert in sales promotion and marketing, he leverages his platform to champion the cause of precision medicine in cancer treatment. His compelling insights have earned him keynote invitations to prestigious events, including the TargetCancer Foundation's 2022 gala and a global conference on precision medicine, where he addressed leading figures in oncology and molecular pathology.

Beyond the lectern, Allen's advocacy takes multiple forms:

  • He is currently serving as a molecular tumour board member (representing the patient’s voice) on ASCO’s TAPUR flagship clinical trial in the United States.
  • He has lent his voice to a television campaign for the Princess Margaret Cancer Foundation and has been featured in film trailers and various international news publications and podcasts.
  • Most recently, Allen was spotlighted on the cover of the Princess Margaret Cancer Foundation's 2023 Annual Report, acknowledging his extraordinary survivorship as a source of inspiration for cancer patients worldwide.

A devoted family man, Allen attributes his remarkable survival journey to the unwavering support of his long-term girlfriend, Cynthia, and their four children. In his leisure time, he channels his competitive spirit into backgammon where he clinched the Intermediate Division title at the 2021 US Open held by the United States Backgammon Federation.

Allen was born and raised in Montreal, Quebec, and now resides in Toronto, Ontario. To learn more about his life, advocacy, and professional endeavors, visit AllenChankowsky.com.

photo

Dr. Neesha Dhani, MD, FRCPC; Medical Oncologist, Princess Margaret Cancer Centre; Assistant Professor, Department of Medicine, University of Toronto

Dr. Neesha Dhani is an Assistant Professor in the Department of Medicine at the University of Toronto and a Staff Medical Oncologist at the Princess Margaret Cancer Centre.

Following medical oncology training, Dr. Dhani completed a clinical drug development and translational research fellowship through the Drug Development Program at the Princess Margaret. This included a Ph.D. at the University of Toronto focused on studying hypoxia-related mechanisms of invasion and metastases in pancreatic cancer.

Dr. Dhani’s clinical focus is in the treatment of women with Gynecologic Cancers, and she developed and continues to lead, the PM/SMH desensitization program to manage patients with platinum HSR.

Since 2020, Dr. Dhani has led important initiatives in developing new models of inpatient care for PM oncology patients and in 2022 was appointed Medical Director of Acute Oncology and Inpatient Care at PM. In this role, Dr. Dhani continues to work to improve the delivery and integration of acute care for oncology patients at UHN.

photo

Hon. Fred Horne, ECA, MBA; Principal, Horne and Associates, Health Policy Consultants; Senior Advisor to 3Sixty Public Affairs; Chair, Mohawk Medbuy Corporation; Former Alberta Minister of Health

Fred Horne is a Canadian health policy consultant and former Alberta Minister of Health. A frequent speaker and panelist on health system issues, he is Principal of Horne and Associates, Health Policy Consultants; Senior Advisor to Ottawa-based 3Sixty Public Affairs; and Chair of Mohawk Medbuy Corporation, a national, not-for profit shared services organization.

Horne serves as Adjunct Professor at the University of Alberta’s School of Public Health and volunteers his time to support policy education and patient engagement initiatives across the country. His career in health policy spans over thirty years. Current areas of focus include value-based health care, seniors care, health system governance and pharmaceutical policy. Horne was appointed a Senior Fellow of the C.D. Howe Institute in January 2023. He is a Director of the Canadian Frailty Network (National Centre of Excellence) and Providence Living (BC).

photo

Dr. Shaqil Kassam, MD, MSc, FRCPC; Medical Oncologist, Stronach Regional Cancer Centre

Dr. Kassam is a Staff Medical Oncologist at the Stronach Regional Cancer Centre in Newmarket Ontario, specializing in the treatment of Thoracic, Gastrointestinal, Neuroendocrine and Genitourinary malignancies. He is also the Skin cancer Lead Oncologist for the Centre and is also the Centre's Immunotherapy and NGS expert where he is instrumental in developing the Molecular diagnostics department at Southlake Regional Health Centre.

Dr. Kassam is currently the Medical Director of research at the Southlake Regional Health Centre, where he has consolidated research activities at the Centre and also facilitates further research in the areas of Cardiology, Medicine and Intensive care. He is also the head of Oncology Research at the Stronach Regional Cancer center - where he has brought several international Phase III randomized trials to the centre. Dr. Kassam is currently the Primary Investigator on several open and in progress trials at the Cancer Centre.

photo

Dr. Robin McGee (dearly departed), Patient Expert, Colorectal Cancer Patient, stage IV

Dr. Robin McGee was a registered clinical psychologist who worked in health and education for over 30 years. Her award-winning book The Cancer Olympics describes her fight for medical justice and fair chemotherapy policy after serious medical negligence. For her advocacy work in cancer care and patient safety, she was decorated with the Sovereign’s Medal for Volunteers by the Governor-General of Canada. Also, she has been awarded the Canadian Cancer Society’s highest honour, the National Medal of Courage. Proceeds of her book go to cancer support programs.

Her blog illustrated her cancer experience using famous rock songs. After years of fighting the disease, Robin succumbed to it in June 2024.

photo

Dr. Ravi Ramjeesingh, MD, PhD, FRCPC; Medical Oncologist & Assistant Professor, Chair of the HPB Cancer Disease Site Group Halifax, Division of Medical Oncology and Department of Community Health and Epidemiology, Nova Scotia Cancer Centre & Dalhousie University

photo

Dr. Brandon Sheffield, MD, FRCPC; Medical Director of Advanced Diagnostics, William Osler Health System; Mississauga Halton Central West Regional Pathology Lead

Speakers

photo

Dr. Shantanu Banerji, BSc(Med), MD, FRCPC; Medical Oncologist, CancerCare Manitoba, MacCharles Site; Senior Scientist, Research Institute in Haematology and Oncology, CancerCare Manitoba; Director, Precision Oncology and Advanced Therapeutics, CancerCare Manitoba; Assistant Professor, Department of Internal Medicine, Section of Haematology/ Oncology, University of Manitoba

photo

Ms. Louise Binder, B.A., LL.B, LL.D (hon ), O.Ont. Health Advocate and Health Policy Consultant, CONECTed - Save Your Skin Foundation

Louise Binder is a lawyer and health policy advocate involved in informing the development of health policy and systemic treatment access practices from a patient perspective for more than 25 years. She started her work in the HIV community in the 1990s after her own diagnosis and before effective treatments were available for HIV. She cofounded the Canadian Treatment Action Council (CTAC) in 1996, that successfully ensured access to treatments and quality care for people living with HIV by working with the federal and provincial governments and other relevant stakeholders to enhance drug review and approval systems, pricing policies and access to liver transplants.

She wrote a Paper on Universal Drug Coverage over a decade ago while Chair of CTAC. She had a special interest in women's issues, chairing the Ontario women's HIV organization Voice of Positive Women for over a decade and working internationally as well. Six years ago Louise began similar work in oncology and is presently Health Policy Consultant for the Save Your Skin Foundation. She has been recognized for her work, receiving an Honorary Doctorate of Laws from her alma mater Queen's Law School, the Order of Ontario from the province of Ontario and two Queen Elizabeth II medals.

photo

Dr. Yvonne Bombard, PhD; Canada Research Chair in Genomics Health Services and Policy; Associate Professor, Institute of Health Policy, Management and Evaluation, University of Toronto; Director, Genomics Health Services Research Program & Scientist, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Unity Health Toronto; Co-Founder & CEO, Genetics Adviser

photo

Dr. Christopher Booth, Professor and Medical Oncologist, Queen's University and Kingston Health Sciences Centre

photo

Dr. Michael Carter, MD, PhD, FRCPC; Medical Director, Molecular Diagnostics, Nova Scotia Health; Medical Director of Research, Division of Anatomical Pathology; Co-Chair, Molecular Oncology Diagnostic Testing Provincial Stewardship Committee for Nova Scotia Health

photo

Ms. Brenda Clayton, MN; Founder, Cholangio-Hepatocellular Carcinoma Canada

photo

Maura Cosgrave, Paediatric Cancer Patient Advocate

photo

Dr. Mary De Vera, B.Sc., M.Sc., Ph.D.; Epidemiologist, Associate Professor, UBC; Tier 2 Canada Research Chair in Health Outcomes and Treatment Adherence

photo

Dr. Shaan Dudani, MBChB, MPH, FRCPC; Medical Oncologist, William Osler Health System; Assistant Professor, University of Toronto

photo

Mrs. Martine Elias, Executive Director, Myeloma Canada

Martine Elias is the Executive Director at Myeloma Canada, the only patient-driven, grassroots organization bringing the Canadian myeloma community together and promoting a strong, unified national voice for people living with multiple myeloma. She has been serving in this role since June 2018.

In addition, Martine is the Co-Chair of the Collective Oncology Network for Exchange, Cancer Care Innovation, Treatment Access and Education (CONECTed), a Canadian network of patient groups working to promote greater education and understanding of cancer therapies to ensure that Canadians have equal, timely and equitable access to these therapies, companion diagnostics, and supportive care.

She is also a member of the founding steering committee of the Patient-Centered Approach to Clinical Trials (PACT) that works to ensure and support the realization of active and equal patient and patient group engagement in cancer clinical trials. In recent years, Martine has been a strong advocate for the use of Real-World Evidence and evidence-based generation research and methodologies to answer uncertain questions when difficult decisions are made of give access to meaningful therapies that demonstrate promising results with only phase II data. She believes the patient voice must be at the table as this evolving data evidence is being shaped.

Martine believes intentional collaboration is key to evolving the knowledge of myeloma for the betterment of patients. In February 2020 she was invited to join the International Myeloma Foundation Board of directors where she is a member of their International Advocacy Committee and their Governance Committee. She also serves to represent Canada on the Myeloma Patient Europe Community Advisory Board (CAB) since 2019 where patient advocates address key challenges patients face in accessing diagnosis, monitoring, treatment, care, and clinical trial at an international level.

Martine started her career in clinical research in the pharmaceutical industry and has since dedicated her professional life to patient advocacy, empowering the patient voice, and helping patients gain access to essential medical treatments. She is passionate about ensuring that the patient voice is included in all aspects of health policy decisions.

Previously, Martine was Director Access, Advocacy and Community Relations at Myeloma Canada where she developed, led, and executed all advocacy strategies and programs.

Prior to that Martine held roles as National Director of Community Relations at Janssen Inc., and Market Access and Health Economics team leader at GSK.

photo

Dr. Cathy Eng, MD, FACP, FASCO; Vanderbilt-Ingram Cancer Center, Nashville, TN; David H. Johnson Chair in Surgical and Medical Oncology; Professor of Medicine, Hematology and Oncology; Director for Strategic Relations; Co-Director, GI Oncology; Co-Leader, Gastrointestinal Cancer Research Program; Director, Young Adult Cancers Program; Co-Chair, NCI Gastrointestinal Steering Committee

Cathy Eng, MD, FACP, FASCO, Professor of Medicine, Hematology and Oncology, is the David H. Johnson Endowed Chair of Surgical and Medical Oncology, Co-Director of GI Oncology and the Co-Leader of the Gastrointestinal Cancer Research Program, Director of Strategic Relations, and the Director of the Young Adults Cancers Program at Vanderbilt-Ingram Cancer Center. She served as the Ambassador for the American Cancer Society ResearcHERS campaign in Nashville (2020-2022). She currently sits on the Board of Directors for the national patient advocacy group, Fight Colorectal Cancer. She is a highly sought mentor and served on the Vanderbilt-Ingram Mentorship Council and is currently a mentor on the T-32 grant and serves as a Professional Development Mentor. She served as the Director of the Developmental Research Program for the GI SPORE.

She continues to assume leadership positions devoted to development of phase I-III clinical trials using novel therapeutics for biomarker discovery and enhanced drug utilization in colorectal, appendiceal and anal cancer. She was awarded the VUMC Biomedical Scientific Impact Award in 2023.

Nationally, Dr. Eng has also been highly active serving on ASCO, ECOG, and SWOG. She has served as the co-chair of the SWOG Rectal/Anal Cancer Subcommittee, the Vice-Chair for the SWOG GI Committee, Chairman of the NCI Rectal/Anal Task Force, served on the NCI GI Steering Committee, and is currently the co-Chair of the NCI GI Steering Committee. She was also chosen as a Fellow of the Executive Leadership in Academic Medicine (ELAM), Class of 2022.

She has published in many peer-reviewed journals including Journal of Clinical Oncology, Lancet, Lancet Oncology, Nature Review, JNCI, New England Journal of Medicine, Annals of Oncology, Cancer, and Annals of Surgical Oncology. She has served as a consultant to the FDA and AHRQ, Cancer Research UK: Training & Career Development Board - Clinician Scientist Fellowship, the Italian Association for Cancer Research, the Dutch Digestive Foundation, the Stand Up to Cancer (SU2C) - Farrah Fawcett Foundation Joint Scientific Advisory Committee (JSAC) and the SWOG Impact Award.

photo

Dr. Harriet Feilotter, PhD, FCCMG; Division Head, Genome Diagnostics, Laboratory Medicine Program, University Health Network; Service Chief, Laboratory Genetics, Kingston Health Sciences Centre; Professor (Adjunct), Department of Pathology and Molecular Medicine, Queen’s University

photo

Ms. Laura Greer, Senior Vice President and National Health Sector Lead, Health and Wellness, Hill & Knowlton; Breast cancer advocate

Laura brings more than 25 years of health public affairs experience, integrating communications, stakeholder, digital and government relations strategies to achieve public policy and business objectives. She has worked extensively in oncology, chronic disease and rare disease, leading advocacy campaigns that engage patients, health professionals and government stakeholders. At H&K, she has led accounts in the pharmaceutical, health professional, digital health, seniors care, hospital, regulator and not-for-profit sectors, including serving as executive director of a patient advocacy organization. Laura has a demonstrated track record of success and an established network of health system partners.

Laura serves as strategic lead for the Cancer Action Now Alliance and the Right2Survive lung cancer campaign.

While having worked professionally in cancer advocacy for many years, it became very personal when Laura was diagnosed with metastatic lobular breast cancer in late 2021. She uses this firsthand patient experience to inform communications and advocacy strategies.

Before joining the firm, Laura spent more than a decade working in Ontario’s hospital sector, gaining first-hand experience inside the health system. She was a senior member of the public affairs team at Toronto’s Hospital for Sick Children (SickKids), focusing on developing and implementing public affairs and public relations programs, including reactive and proactive media relations, internal communications and issues management. As head of the research public affairs portfolio, Laura built the public profile of the SickKids Research Institute, with a particular focus on genetics, genomic and stem cell research. She also developed government and stakeholder relations programs to secure sustainable funding for research and innovation.

Laura holds a bachelor of arts (honours) in political science from McGill University and a graduate diploma in journalism from Concordia University and worked in print journalism before entering the field of public affairs.

She lives in Toronto with her husband and two teenage sons.

photo

Dr. Denis Horgan, PhD, LLM, MSc, BCL; Executive Director, European Alliance of Personalised Medicine (EAPM); Editor in Chief, Public Health Genomics Journal; Chair of the Stakeholder Advisory Group, International Cancer Genome Consortium

photo

Mr. Don Husereau, BSc Pharm, MSc; Adjunct Professor of Medicine, University of Ottawa

photo

Mr. Craig Ivany, MBA; Chief Provincial Diagnostics Officer, Provincial Health Services Authority, British Columbia

photo

Dr. Jason Karamchandani, Associate Professor, Departments of Pathology, Neurology and Neurosurgery, McGill University; President, Canadian Association of Pathologists

photo

Dr. Pashtoon Kasi, MD, MS; Oncologist and Researcher, Weill Cornell Medicine and New York-Presbyterian Hospital; Director for Colorectal Cancer Research, Weill Cornell Medicine; Precision Medicine Director for Liquid Biopsy Research, Englander Institute of Precision Medicine

Dr. Pashtoon Kasi, MD, MS is an oncologist and researcher at Weill Cornell Medicine and New York-Presbyterian Hospital. He focuses on treating patients with gastrointestinal (GI) cancers and the treatment of patients with novel drugs/early-phase clinical trials. At Weill Cornell Medicine, Dr. Kasi additionally serves as the Director for Colorectal Cancer Research, as well as Precision Medicine Director for Liquid Biopsy Research at the Englander Institute of Precision Medicine.

Dr. Kasi received his medical degree from the prestigious Aga Khan University (AKU) in Pakistan in 2006. He did a year of internship at the University of Texas Health Science Center at San Antonio (UTHSCSA) in 2009. Following this Dr. Kasi completed his residency at the International Scholars Program (ISP) at the University of Pittsburgh Medical Center (UPMC). Subsequently in 2016 he completed a fellowship in oncology and hematology at the Mayo Clinic. At the Mayo Clinic, he also completed a post-doctoral master’s program at the Mayo School of Graduate Medical Education (MSGME) in clinical and translational sciences (Masters in Basic Sciences).

Prior to joining Weill Cornell Medicine, Dr. Kasi served as an Associate Professor of Medicine at the Division of Hematology and Oncology at the University of Iowa. Before that, he was an Assistant Professor of Medicine and Oncology at both University of Iowa and Mayo Clinic. Dr. Kasi was one of a select few who were appointed to the academic post of Assistant Professor of Oncology and Assistant Professor of Medicine at the Mayo Clinic during his fellowship due to his research and academic achievements.

Dr. Kasi’s research focus has been on “liquid biopsies” [(circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs)], alongside developing and conducting clinical trials focused on precision oncology and precision medicine. Dr. Kasi is an author and editor of several books including: “Research: What, Why and How: A Treatise from Researchers to Researchers”, and “Impact of circulating tumor DNA (ctDNA) in Patients with Gastrointestinal Malignancies” and has over 100 publications in leading peer-reviewed journals. Additionally, Dr. Kasi has been active as a principal investigator on numerous investigator-initiated, industry-sponsored as well as cooperative group clinical trials in oncology.

photo

Ms. Emmanuelle Langelier, Caregiver to her husband, stage 4 rectal cancer patient

Emmanuelle Langelier is 44 years old and a caregiver to her 39 years old husband diagnosed with stage 4 rectal cancer in December 2022. Her husband was having symptoms for many months, but having no prior health issues, no family doctor and had been on the lowest priority list for 4 years before he got assigned a clinic. It took almost 6 months between the time he finally saw a doctor to the time he was diagnosed. He always seems to be falling between the cracks of the Health Care System and she is fighting for his life as hard as he is.

Emmanuelle is a Federal Public Servant living in the province of Quebec. She believes we can all come together to make the Canadian Health Care System better. Stage 4 cancer does not have to be what the books say it has to be. She is here to find solutions.

photo

Dr. Darren Larsen, MD, CCFP, MPL; Chair, Cancer Quality Council of Ontario; Board Director, Canadian Partnership Against Cancer; Senior fellow, Women’s College Hospital Institute for Health System Solutions and Virtual Care; Lecturer, Department of Family and Community Medicine and Institute for Health Policy Management and Evaluation, University of Toronto

Over his 33 years as a comprehensive care Family Physician, Darren has been involved in many provincial and national Health IT, Quality and Physician Leadership initiatives in Canada. He has contributed to multiple digital health, primary care and quality commissions for the Ontario Ministry of Health, Ontario Health (Quality, Digital Services and Cancer Care) as well as the Ontario and Canadian Medical Associations. He is Chair of the Cancer Quality Council of Ontario, Board Director for the federal agency Canadian Partnership Against Cancer, and is a senior fellow at WIHV (Women’s College Hospital Institute for Health System Solutions and Virtual Care). Most recently Darren has held senior executive positions at Accenture and TELUS Health. His digital health interests include data analytics, measurement for quality improvement and accountability, physician change and issues of scale and spread.

Darren obtained his Bachelor of Science at the University of Alberta, Medical Doctorate at the University of Calgary, did residency at the University of Ottawa and holds a Masters Certificate in Physician Leadership from York University’s Schulich School of Executive Management. He was most recently Chief Medical Director of TELUS Health Care Centres nationally, practices at Women’s College Hospital, and teaches at the University of Toronto in the Department of Family and Community Medicine as well as the Institute for Health Policy Management and Evaluation.

photo

Mrs. Richelle Laturnus, BSc; Support Services Manager, Prostate Cancer Foundation Canada

Richelle is the Support Services Manager at Prostate Cancer Foundation Canada, a grassroots nonprofit that has provided leadership and resources in prostate cancer support, awareness, and research for over 25 years. Richelle oversees Prostate Cancer Foundation Canada's patient and partner support services, including their local and nationwide support groups, educational initiatives, and awareness programs which reach patients and their loved ones across Canada.

Through her degree in Population and Quantitative Health, she found herself increasingly interested in improving health equity within the non-profit sector. She is particularly passionate about increasing accessibility to, and awareness of, fair, equitable, and quality health and support services for anyone affected by prostate cancer in Canada.

photo

Ms. Sang Mi Lee, MBA, BSc Phm, RPh; Executive Director, MORSE Consulting Inc.

Sang Mi is a passionate healthcare leader and pharmacist with Global Executive MBA in Healthcare and Life Sciences. She is currently the Executive Director at MORSE Consulting Inc. and has 20 years of unique healthcare experience (public, pharmaceutical industry, consulting, and not-for-profit). She was both Senior Manager and Senior Pharmacist at the pan-Canadian Pharmaceutical Alliance (pCPA) Office and was responsible for strategic planning, finances, operations, recruitment, and stakeholder management as well as leading and supporting pan-Canadian negotiations and reimbursement policy developments.

She was also an Access Lead in Personalized Healthcare and Precision Oncology at Hoffmann-La Roche immediately prior to joining MORSE. In addition, Sang Mi has held various roles within the Ontario Public Drug Programs, including managing the Exceptional Access Program.

photo

Dr. Christopher Lieu, MD; Associate Professor, Director, GI Oncology, University of Colorado

photo

Dr. Catalina Lopez-Correa, MD, PhD; Chief Scientific Officer, Genome Canada

Dr. Lopez-Correa is the Chief Scientific Officer (CSO) at Genome Canada. Dr. Lopez-Correa has dedicated her career to genomics and its transformative applications in life sciences in Canada and internationally. As CSO at Genome Quebec (2008-2015) and Genome BC (2015-2019), she was instrumental in developing competitive teams for research and innovation initiatives raising the profile of Canadian genomics on the global stage. Recently, as the Executive Director of the Canadian COVID19 Genomics Network (CanCOGeN) she led a $40M initiative to advance the use of genomics to understand and control the COVID19 pandemic. Now, as CSO of Genome Canada, and as a breast cancer survivor, she is taking genomics to the next level, by advancing the national and global implementation of genomic technologies.

Dr. Lopez-Correa’s work has been recognized with several awards. In 2017 the Canadian Senate 150th Anniversary Medal, in 2013 the National Order of Merit from Colombia.

photo

Ms. Cassandra Macaulay, BSc, MHS, RTNM; Senior Manager of Programs & Education, CCRAN

photo

Dr. Ceilidh MacPhail, MSc, MD; Medical Oncologist, Nova Scotia Cancer Center

Dr. MacPhail is a Medical Oncologist who works at the Nova Scotia Cancer Centre. She sees patients with Thoracic malignancies (Lung, Mesothelioma, Upper GI) and Sarcoma (soft tissues and bone).

Her previous training includes a Master of Science in Global Health focusing on epidemiology. Dr. MacPhail has been very fortunate to complete all her medical training at Dalhousie University. She joined the Division of Medical Oncology in Halifax this past year. As a new staff member, she looks forward to advocating for enhanced accessibility to cancer care in Nova Scotia.

photo

Dr. Mita Manna, MD, FRCPC; Medical Oncologist, Provincial Disease Site Lead for Breast Malignancies, Saskatoon Cancer Centre

photo

Dr. Michael Mengel, MD; Chair & Medical Director, Laboratory Medicine & Pathology, University of Alberta; Medical Director, Alberta Precision Laboratories Ltd.

Dr. Mengel is Chair and Medical Director for Laboratory Medicine and Pathology at the University of Alberta and with Alberta Precision Laboratories Ltd. in Edmonton, Canada.

He studied medicine at the Semmelweiss University in Budapest, Hungary before going on to specialise in pathology and further in transplantation pathology and nephropathology. Before moving to Edmonton he provided transplant pathology service at the Hannover Medical School, Germany. As a sub-specialized Transplantation and Renal Pathologist, Dr. Mengel is engaged in various international sub-specialty societies related to nephropathology and organ transplantation and has published widely in his field. His current work is focused on applying molecular techniques to biopsy specimens, with the aim to increase diagnostic precision in organ transplantation.

photo

Mr. Ken Noel, Executive Director, The Walnut Foundation

Initially diagnosed in late 2012 after two years of rising PSA levels and three Biopsies. Although initial diagnosis was a low grade cancer, the final pathology report, after surgery, revealed a more aggressive cancer which required further radiation treatment.

Mr. Noel’s own research into his cancer revealed a lack of information about prostate cancer incidences in black men in Canada and a silence within the Black Community about this disease. In response, he joined the Walnut Foundation in 2014 to lend his experience in their mandate to increase awareness in the Back Communities. Mr. Noel’s work with The Walnut Foundation included organizing and chairing the annua health conference, 4 years as the President of the Foundation, and his current role as Executive Director with a mandate to grow the Foundation.

photo

Dr. Nicola Normanno, MD; Scientific Director, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy

Dr. Nicola Normanno was born in Ottaviano (Italy) in 1964 and graduated cum laude in Medicine and Surgery in 1988. He worked as postdoctoral fellow in the National Cancer Institute of Bethesda (USA), then he specialized in Medical Oncology and later in Hematology. In 2004 he won the “Annals of Oncology Prize for Translational Research” and in 2005 he became Adjunct Associate Professor at the Temple University of Philadelphia. In 2005 he was appointed as Director of the Cell Biology and Biotherapy Unit of INT Fondazione “G. Pascale”, and in 2006 as the Chairman of the Research Department of the same institute. He is currently the Scientific Director of the IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori" in Meldola.

Dr. Normanno leads a research group involved in both pre-clinical and clinical studies, with particular regard to the identification of biomarkers associated with sensitivity/resistance to target-based agents in clinical development. Dr. Normanno’s group has been one of the first to use next generation sequencing (NGS)-based techniques in clinical trials. His group has a relevant expertise in liquid biopsy. Dr. Normanno is also involved in clinical diagnostics and in the organization of national and international external quality assessment (EQA) schemes in molecular pathology.

Dr. Normanno is a member of many national and international cancer research associations (AACR, GOIM, AIOT, ESMO, AIOM, SIC, FONICAP). He is President Elect of the Italian Society of Cancerology (SIC). Dr. Normanno is author of more than 200 publications in international journals and he is a reviewer for many peer reviewed journals.

photo

Ms. Teresa Norris, Founder and President, HPV Global Action

Teresa Norris is a passionate Sexual Health Specialist with an expertise on Human Papillomavirus (HPV) and sexual health issues with over 17 years’ experience. She uses evidence-based communication methods and champions disease prevention strategies. She is also the President of HPV Global Action.

In 2006, Teresa founded HPV Global Action/VPH Action Globale, a bilingual registered charity offering forward-thinking research initiatives and programs in healthcare and academic settings and has developed synergies at different organizational and governmental levels evolving from local initiatives and up to the international stage.

Her focus is educating people of all ages about sex-positive and inclusive sexual and reproductive health, while emphasizing HPV and its potential consequences – which include nine preventable HPV-related cancers. With the support of her team and healthcare professionals across Canada and around the world, HPV Global Action is working to ensure countries offer equitable access to HPV prevention, cervical screening and access to treatment/care both in Canada and internationally.

Teresa is currently leading an international team that is putting forth a women-centred health implementation research project using integrated approaches to ensure sustainable systemic change for women in Sub Saharan Africa through a «one-stop shop» approach to offer women ranging 20-49 y.o. an opportunity to address their gynaecological needs during a two-hour visit, starting in Eswatini in September 2022. This project will be addressing four World Health Organization (WHO) 2030 objectives for disease control and elimination of: Cervical Cancer, Female Genital Schistosomiasis (FGS), Human Immunodeficiency Virus (HIV), and treatment of Soil transmitted helminths.

photo

Prof. Klaus Pantel, Chairman, Institute of Tumor Biology, University Medical Center Hamburg-Eppendorf (UKE)

photo

Prof. Dr. Patrick Pauwels, MD, PhD; Head of the Laboratory of Molecular Pathology & Co-Director of the Center of Oncology Research (CORE), Antwerp University; Professor in Molecular Oncopathology, Antwerp University; Scientific Advisor, Luxemburg National Health Service

Prof. Dr. P. Pauwels obtained his MD certificate at the Catholic University of Leuven, Belgium in 1985. After a two-year fellowship in Internal Medicine, he started a residency in Pathology at the University of Leuven. He then worked as a staff pathologist in Eindhoven (NL) till 2002. He went to the Maastricht University Medical Center (NL) till 2005. From 2005 till 2009 he was pathologist at the Ghent University Hospital, Belgium. Since 2009 he works at the Antwerp University Medical Center. He obtained his PhD at the University of Leiden in 2004 in the field of molecular pathology (“Bridging the gap between cytogenetics and pathology of soft tissue tumours”).

He is head of the laboratory of molecular pathology and co-director of the Center of Oncology Research (CORE) of the Antwerp University.

He became professor in Molecular Oncopathology at the Antwerp University in 2012 and is scientific advisor of the Luxemburg National Health Service since 2013.

His principal interest is biomarker research in oncology, with a particular focus on liquid biopsy in cancer.

Prof Pauwels is Member of several societies: the American Association for Cancer Research, Member of the American Society of Clinical Oncology (ASCO), Member of the ‘International Association of the Study of Lung Cancer (ISALC), Member of European Respiratory Society (ERS), Member of the European Society for Medical Oncology (ESMO), Member of the Belgian Society of Medical Oncology (BSMO), Member of the lung cancer group of the EORTC.

photo

Dr. Michael Raphael, MD, FRCPC; Medical Oncologist, Odette Cancer Center, Sunnybrook Health Sciences Centre

photo

Mrs. Martha Raymond, MA, CPN; Founder/CEO, The Raymond Foundation; Founding Executive Director, GI Cancers Alliance

Martha Raymond is the Founder/CEO of The Raymond Foundation and serves as the Founding Executive Director of the GI Cancers Alliance. For over thirty-five years, Martha has been a passionate and dedicated advocate for cancer patients and caregivers. Martha has published numerous research articles in peer-reviewed journals including the Journal of Clinical Oncology, Cancer, and the Journal of Cancer Research. Martha’s research focuses on patient-reported outcomes to ensure that the patient voice and lived-experience is understood, valued, and considered throughout the care continuum.

Martha is a certified professional facilitator and serves as a frequent speaker and moderator for global oncology conferences and symposiums. Martha also serves as an oncology consultant specializing in program development for clients in academia, pharmaceutical industry, and global advocacy organizations.

In 2023 Martha was honored to receive two awards for her advocacy and research efforts: Excellence in Colorectal Cancer Advocacy by the WunderGlo Foundation, California and the Luminary Award in GI Cancers by Onc Live and the Ruesch Center / Lombardi Comprehensive Cancer Center at Georgetown University.

Martha holds advanced graduate certifications in Integrative Medicine, Hospice Counseling, Palliative Care and Patient Navigation. As a life-long learner, Martha is a current executive education student at Harvard University Kennedy School.

photo

Ms. Filomena Servidio-Italiano, Hon B.Sc., B.Ed., M.A.; President & CEO, CCRAN

Filomena is the President and CEO of the Colorectal Cancer Resource & Action Network (“CCRAN”) – a patient-focused organization championing the health and wellbeing of Canadians touched by colorectal cancer and others at risk of developing the disease. Her undergraduate and graduate work lie in the biological sciences and educational studies. As a caregiver to her father, who was afflicted with and succumbed to metastatic cancer, his journey has served as the impetus for the founding of CCRAN, one month post his passing in August of 2006.

The past seventeen years have been dedicated to the cause of supporting, educating, and advocating on behalf of colorectal cancer patients and caregivers, to improve patients’ quality of life and longevity by furnishing evidence-based information and access to unique and novel patient programs, such as CCRAN’s innovative “My CRC Consultant”, an online tool providing the metastatic patient with evidence-based and expert reviewed, potential therapeutic options based on the patient’s tumour’s molecular profile. She has been working closely with valued health care professionals across the continuum of colorectal cancer care to ensure content acumen in the management of colorectal cancer. She is humbled to be published alongside world-renowned experts in areas such as colorectal cancer management, PROs and PROMs, early age onset colorectal cancer awareness and education, promoting national LDLT efforts, education on molecular profiling, and more.

Filomena is a strong proponent of HTA patient evidence submissions since the inception of pCODR, ensuring the patient voice is captured and well incorporated into her HTA patient evidence submissions. She prepares these submissions not only for colorectal cancer drug therapies under review, but within therapeutic areas for which there are no representative patient advocacy groups or on behalf of patient advocacy groups who may not have the capacity to make these critically important submissions. She strives to secure robust patient and caregiver participation to help identify patients’ unmet needs, as well as capture their fundamentally important values, preferences, and priorities with the goal of ultimately ensuring reimbursement of effective treatments based on thoughtful and compelling input. She continues to be a passionate advocate for the Canadian cancer patient and their caregiver.

ABOUT CCRAN

The Colorectal Cancer Resource & Action Network (“CCRAN”) is a national, not for profit patient organization dedicated to supporting, educating, and advocating on behalf of colorectal cancer patients and caregivers across Canada to help improve the quality of life and longevity for patients diagnosed with colorectal cancer. It is a patient-focused organization whose programs are inspired by two patient advisory councils, one of which is dedicated to Early Age Onset Colorectal Cancer (EAOCRC). CCRAN has expanded its mandate to now be serving a population of cancer patients outside of the colorectal cancer space through their HTA patient evidence submissions, educational events and advocacy initiatives to help reduce the burden of cancer in Canada.

photo

Dr. Monika Slovinec D’Angelo, VBHC Expert; Chief Research Officer, CCRAN

photo

Dr. Stephanie Snow, MD, FRCPC; Medical Oncologist, QEII Health Sciences Centre; Professor, Faculty of Medicine, Dalhousie University; President, Lung Cancer Canada

photo

Dr. Joao Paulo (JP) Solar Vasconcelos, MD; Gastrointestinal Medical Oncology Fellow, BC Cancer, Vancouver

photo

Dr. Alan Spatz, MD, MSc; Professor, Departments of Pathology and Oncology, McGill University; Chief, Department of Clinical laboratory medicine, McGill University Health Center (MUHC); Medical director, Optilab Montreal-MUHC network

Dr. Alan Spatz is professor of pathology and oncology at McGill university, chief of the department of Clinical laboratory medicine at the McGill University Health Center (MUHC), and medical director of Optilab Montreal-MUHC that is an integrated network of labs belonging to the McGill affiliated hospitals. He is also director of the molecular pathology center at the Lady David Institute (LDI)/Jewish General Hospital of Montreal, and of the “X chromosome and cancer” research lab at the LDI.

Dr. Spatz received his medical education at the Sorbonne university, Paris, France, and worked at the Gustave Roussy cancer institute in Villejuif, France, from 1994 to 2008.

Dr. Spatz serves on the board and steering committee of several international and Canadian research organizations that include the WIN Consortium (winconsortium.org), Exactis Innovation (exactis.ca), and the Canadian BEAT-cancer coalition for advanced molecular diagnostics. He is currently co-chair of the Correlative sciences committee of the Canadian Cancer Trials Group (CCTG) and the president of the Oncology committee of the Quebec Network of Molecular Diagnostic (RQDM). He was chair of several clinical research organizations, including the Melanoma group of the European Organization for Research and Treatment of Cancer (EORTC), the Pathobiology group of the EORTC that he founded, the Melanoma committee of the CCTG, and was president of the French division of the International Academy of Pathology.

Dr. Spatz’ research is focused on cancer biomarkers and on the role of the X chromosome-related haploinsufficency in cancer progression. He has published more than 230 peer reviewed articles and books in highly ranked journals including Nature Medicine, Nature Cancer, Nature Cancer Reviews, Lancet, Science Translational Medicine, Science Immunology, Annals of Oncology, and Journal of Clinical Oncology.

photo

Dr. David J. Stewart, MD; Professor of Medicine, Division of Medical Oncology, University of Ottawa and The Ottawa Hospital

photo

Prof. David Thomas, Director, Centre for Molecular Oncology, University of New South Wales; Head of the Genomic Cancer Medicine Laboratory, Garvan Institute of Medical Research; CEO, Omico

photo

Dr. Laura Weeks, PhD; Director, Health Technology Assessment, CADTH

photo

Dr. Stephen Yip, Associate Professor, UBC; Clinician-Scientist, Neuropathologist, BCCA; Associate Member at Canada’s Michael Smith Genome Sciences Centre

Webcast powered by Resolve Collaboration Services
Copyright © 2024 all rights reserved.